PHIA Koninklijke Philips NV

May 10, 2023 

The hospital will be equipped with state-of-the-art diagnostic and therapeutic oncology solutions over the next three years, contributing to enhanced patient care

Amsterdam, the Netherlands, Stockholm, Sweden, and Madrid, Spain – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, radiation therapy leader Elekta (EKTA-B.ST), and oncology service provider Mercurius Health today announced the signing of a 3-year agreement under which Philips and Elekta will install state-of-the-art diagnostic and therapeutic oncology equipment and associated informatics solutions at Mercurius Health’s newly-acquired Robert Janker Klinik cancer center in Bonn, Germany. The investment in Philips and Elekta solutions by Mercurius Health is part of its commitment to establishing a major presence in Germany, following the company’s acquisition of Robert Janker Klinik earlier this year.  

The agreement has been enabled by the strategic partnership between Philips and Elekta to advance comprehensive personalized cancer care through the deployment of precision oncology solutions. The Robert Janker Klinik, a specialized hospital in oncology and palliative care, focuses on minimally invasive diagnostics and treatments for cancer. The hospital has three inpatient departments (radiology, radiotherapy and palliative care) and an outpatient unit for radiotherapy. It employs around 130 staff and treats patients from across the region as well as national and international patients.

“This major investment in cutting-edge technology by Mercurius Health means many of the projects currently in planning can be rapidly moved forward, making us a showcase for what the future of cancer care will look like,” said Prof. Dr. Attila Kovács, Head Physician of the Clinic for Diagnostic and Interventional Radiology and Neuroradiology.

“The combination of Philips’ diagnostic imaging and oncology informatics solutions, and Elekta’s radiation therapy solutions means we will be able to offer our patients state-of-the-art therapy for tumors such as prostate and liver cancer that are currently difficult to treat, improving clinical outcomes,” said Prof. Dr. Michael Pinkawa, Radiation Oncologist and Head of Radiotherapy at Robert Janker Klinik.

Bringing data and actionable insights to the benefit of cancer patientsTo make a precise and informed diagnosis and select the optimal therapy for each individual cancer patient, oncologists often need to consider and scrutinize around 10,000 data points, many of which reside in disparate IT systems – electronic medical records, lab systems, radiology, pathology, and genomics. Philips and Elekta bring all this data together and translate it into actionable insights, and pathways with predictable outcomes for each patient [1].

The combined solutions enable oncologists to deliver precise and personalized therapies that treat tumors effectively while sparing adjacent tissue and organs at risk. Installed in Robert Janker Klinik, they will provide Mercurius Health with a platform to showcase its consultancy and B2B oncology services in the German market and continue its pioneering work in increasing productivity, improving patient and staff experience, and enhancing clinical care.

[1] Results from case studies are not predictive of results in other cases. Results in other cases may vary.

For further information, please contact:

Mark GrovesPhilips Global Press OfficeTel: +31 631 639 916E-mail: mark.groves@philips.com

Mattias ThorssonVice President, Head of Corporate Communications, Elekta Tel: +46 70 865 8012E-mail: mattias.thorsson@elekta.com

Laura Terzagui FernándezDirector of Marketing & Communications, Mercurius HealthTel: +34 650 446 543E-mail: laura.terzagui@mercuriushealth.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About ElektaAs a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.

About Mercurius HealthMercurius Health is the European leader of B2B services to hospitals and oncology centers with specializations in radiotherapy, nuclear medicine and radiology. Services include advisory, remote planning, commissioning, training & education, outsourced operations and financing of equipment used in centers and are mostly provided in Europe and Africa. www.mercuriushealth.com

Attachment

• Clinicians looking at screen

Grafico Azioni Koninklijke Philips NV (BIT:PHIA)
Storico
Da Nov 2024 a Dic 2024

Grafico Azioni Koninklijke Philips NV (BIT:PHIA)
Storico
Da Dic 2023 a Dic 2024